A Colomer¹, N Erill¹, M Górriz^1,2, M Verdú², R Roman¹, R Ibáñez¹, C Cordon-Cardo¹ and X Puig^1,2.

¹BIOPAT. Biopatologia Molecular, SL, Grup Assistència, Barcelona, Spain and ²Histopat Laboratoris, Barcelona, Spain.

Background: Topoisomerase II-alpha gene (TOP2A) aberrations have been recently pointed as predictive markers of anthracycline-based adjuvant chemotherapy in breast cancer. While coamplification of ERBB2 and TOP2A seems […]

Montse Verdú¹, Anna Colomer², Ruth Román², Nadina Erill², Miquel Calvo³, Abelardo Moreno¹, Carlos Cordon-Cardó⁴, Xavier Puig ^1,2.

¹HISTOPAT Laboratoris, Barcelona. ²BIOPAT, Biopatologia Molecular, Barcelona. ³Departament d’Estadística de la Universitat de Barcelona, Barcelona y ⁴Division of Molecular Pathology,  Memorial Sloan-Kettering Cancer Center,  New York, USA.

The HER2/neu proto-oncogen is frequently amplified in breast cancer, and serves as a […]

Verdú M^1, Colomer A^2, Román R^2, Erill N^2, Moreno A^1, Cordón-Cardo C^1,2, Puig X^1,2.

¹HISTOPAT Laboratoris & ²BIOPAT. Grup Assistència. Barcelona (Spain).

HER-2/neu is a critical marker in assessing the molecular profile of breast cancer, as it represents a target for therapeutic intervention. HER-2/neu gene amplification has been reported to be associated with treatment response. Immunohistochemistry (IHC) […]

M. Guix Pericas ^1,2, C. Cordón Cardó ^1,2,3, M. A. Cañadas Bouzas ¹, A. Colomer Valero ²,  X. Puig Torrus ^1,2.

¹HISTOPAT S.A. Laboratoris. ²BIOPAT. Biopatologia molecular S.L. Grup Assistència. Barcelona. ³Memorial Sloan Kettering Cancer Center. Division of Molecular Pathology. Nueva York.

INTRODUCCIÓN

El carcinoma de mama es una de las neoplasias malignas más frecuentes y una de […]